首页> 美国卫生研究院文献>other >Translating Microfluidics: Cell Separation Technologies and their Barriers to Commercialization
【2h】

Translating Microfluidics: Cell Separation Technologies and their Barriers to Commercialization

机译:翻译微流体:细胞分离技术及其商业化障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Advances in microfluidic cell sorting have revolutionized the ways in which cell-containing fluids are processed, now providing performances comparable to, or exceeding, traditional systems, but in a vastly miniaturized format. These technologies exploit a wide variety of physical phenomena to manipulate cells and fluid flow, such as magnetic traps, sound waves and flow-altering micropatterns, and they can evaluate single cells by immobilizing them onto surfaces for chemotherapeutic assessment, encapsulate cells into picoliter droplets for toxicity screenings and examine the interactions between pairs of cells in response to new, experimental drugs. However, despite the massive surge of innovation in these high-performance lab-on-a-chip devices, few have undergone successful commercialization, and no device has been translated to a widely distributed clinical commodity to date. Persistent challenges such as an increasingly saturated patent landscape as well as complex user interfaces are among several factors that may contribute to their slowed progress. In this article, we identify several of the leading microfluidic technologies for sorting cells that are poised for clinical translation; we examine the principal barriers preventing their routine clinical use; finally, we provide a prospectus to elucidate the key criteria that must be met to overcome those barriers. Once established, these tools may soon transform how clinical labs study various ailments and diseases by separating cells for downstream sequencing and enabling other forms of advanced cellular or sub-cellular analysis.
机译:微流控细胞分选技术的进步彻底改变了含细胞流体的处理方式,如今其性能可与传统系统媲美,甚至超越传统系统,但形式却大大缩小了。这些技术利用各种各样的物理现象来操纵细胞和流体流动,例如磁阱,声波和改变流量的微模式,并且它们可以通过将单细胞固定在表面上进行化学治疗评估来评估单细胞,将细胞封装成皮微升液滴以用于毒性筛选并检查细胞对新的实验药物的相互作用。然而,尽管这些高性能芯片实验室设备的创新浪潮很大,但几乎没有成功的商业化应用,并且迄今为止,还没有设备被转化为广泛分布的临床商品。持续的挑战,例如日益饱和的专利格局以及复杂的用户界面,都是导致其进展缓慢的几个因素。在本文中,我们确定了几种领先的微流控技术,用于对准备进行临床翻译的细胞进行分选;我们研究了阻碍其常规临床使用的主要障碍;最后,我们提供了一份招股说明书,以阐明克服这些障碍所必须满足的关键标准。这些工具一旦建立,就可以通过分离用于下游测序的细胞并启用其他形式的高级细胞或亚细胞分析,很快改变临床实验室研究各种疾病的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号